Eli Lilly and Company

Miles Goodman Siegel

Russell Dean Stucky

Yao-Chang Xu

Stephen W Kaldor

James E Fritz

Charles Howard Mitch

David Andrew Coates

Kumiko Takeuchi

Daniel Jon Sall

Theo Schotten

Patric James Hahn

Steven Marc Massey

Steven James Quimby

Jason Kenneth Myers

Kevin Charles Fortner

Cynthia Darshini Jesudason

Wolfgang Stenzel

Qing Shi

Richard Duane Johnston

David Michael Remick

John Arnold Werner

Nuria Diaz Buezo

Concepcion Pedregal-Tercero

Maria-Jesus Blanco-Pillado

Gerd Ruehter

Mark Donald Chappell

William Glen Holloway

Jennifer Anne McMahon

Rushad Eruch Karanjawala

Britta Evers

Chad Nolan Wolfe

Marta Garcia De La Torre

Antonio Navarro

Elizabeth Marie Thomas

James Edward Matt

Dana Rae Smith

Jennifer Anne Mcmahon

James Erwin Fritz

James Edward Junior Matt

The present invention provides a compound of Formula II: or a pharmaceutically acceptable salt or hydrate thereof, useful as a CGRP receptor antagonist.

3-methyl-pyrrolidine-2,5-dione derivatives useful as CGRP receptor antagonists

The present invention provides a compound of Formula II: or a pharmaceutically acceptable salt thereof.

CGRP receptor antagonists

A compound of the formula (I) or a pharmaceutically acceptable salt, enantiomer, racemate, diasteromers or mixtures thereof, or a solvate thereof, formulations and methods of use thereof, as opioid receptor antagonists are disclosed wherein the variables are as described herein. 

6-substituted nicotinamide derivatives as opioid receptor antagonists

A compound of the formula (I) wherein the variables X, X, B, D, Rto Rincluding R, p, y, q, and z, are as defined or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer or mixtures thereof, useful for the treatment, prevention or amelioration of obesity and Related Diseases is disclosed. 

Opioid receptor antagonists

A compound of the formula (I) or a pharmaceutically acceptable salt, enantiomer, racemate, diastereomers or mixtures thereof, or a solvate thereof, formulations and methods of use thereof, as opioid receptor antagonists are disclosed wherein the variables are as described herein. 

A compound of the formula (I) wherein the variables X, X, B, D, Rto Rincluding R, p, y, q, and z, are as defined or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer or mixtures thereof, useful for the treatment, prevention or amelioration of obesity and Related Diseases is disclosed 

Diphenylether amide derivatives as opioid receptor antagonists

The present invention relates to a &bgr; adrenergic receptor agonist of formula (I) or a pharmaceutical salt thereof, which is capable of increasing lipolysis and energy expenditure in cells and, therefore, is useful for treating Type II diabetes and/or obesity. The compound can also be used to lower triglyceride levels and cholesterol levels or raise high density lipoprotein levels or to decrease gut motility. In addition, the compound can be used to reduced neurogenic inflammation or as an antidepressant agent. Compositions and methods for the use of the compounds in the treatment of diabetes and obesity and for lowering triglyceride levels and cholesterol levels or raising high density lipoprotein levels or for decreasing gut motility are also disclosed.

&bgr;3 adrenergic agonists

This invention provides novel 5-HT.sub.1F agonists of Formula ##STR1## where X, R.sup.1, R.sup.2, and R.sup.3 are defined in the specification, which are useful for the treatment of migraine and associated disorders.

Polymer bound carbodiimide coupling reagent

The present invention relates to compounds used for increasing activation of the 5-HT1F receptor.

Carbodiimide coupling reagent

N-�2-substituted-3-(2-aminoethyl)-1H-indol-5-YL!-Amides: new 5-HT.sub.1F

Growing community of inventors

Indianapolis, IN, United States of America

Miles Goodman Siegel